Prevail InfoWorks

Women’s Entrepreneurship Day 2025 Today is a reminder of the women who build, lead, and inspire every day. From early-stage founders to seasoned executives, women entrepreneurs continue to shape industries and open doors for others. At Prevail InfoWorks, we are especially proud to be led by a woman Executive Chairman who embodies that spirit of innovation and courage. Empowering women entrepreneurs isn’t just the right thing to do; It fuels real economic and social impact. Take a moment today to celebrate the women entrepreneurs who inspire you. Who is a woman leader that is inspired your own path? #WEDO2025 #JoinWEDO #ChooseWOMEN #WomenWOW #WomensEntrepreneurshipDay #WomenInBusiness #WomenInLeadership #Entrepreneurship #FemaleFounders #Innovation #Leadership #BusinessLeadership #PrevailInfoWorks #Prevail #RiseAbove

A Major Step Forward for Patients Facing Drug-Resistant Malaria Malaria continues to impact millions of families across Africa, and rising treatment resistance has made care even more challenging. New data from Novartis offers renewed hope for patients who depend on medicines that remain effective. What the new findings show: -GanLum achieved cure rates as high as 99.2 percent in a large phase 3 study of 1,688 adults and children -Patients receiving GanLum cleared symptoms and baseline parasites at rates that matched or exceeded today’s standard of care  -Early analyses show GanLum works well against parasites carrying mutations linked to partial artemisinin resistance  -Patients also saw rapid reduction of mature gametocytes which drive ongoing transmission in communities Artemisinin resistance threatens the medicines millions rely on, especially children who can progress to severe disease within hours. An effective therapy against resistant parasites could offer families in high burden regions new hope, and while long term questions remain, GanLum’s phase 3 data is an encouraging step forward. How could this shift the outlook for families in regions where treatment resistance is growing? What role can new treatment options play as climate change shifts malaria patterns? "GanLum showed high efficacy against multiple forms of the parasite" Abdoulaye Djimdeé, Ph.D., professor of parasitology and mycology at the University of Science, Techniques and Technologies of Bamako, Mali, said. Read the full article in the comment section #Malaria #GlobalHealth #PublicHealth #DrugDevelopment #HealthcareImpact #GlobalHealthSecurity #AfricaHealth #Prevail #PrevailInfoWorks #RiseAbove

The conference is officially underway, and Prevail InfoWorks is energized to be here among leaders shaping the future of oncology clinical trials. If you are attending, visit Table 4 to see how we are supporting oncology programs from early phases through pivotal trials. Our team is showcasing real-world oncology case studies and live study exploration using the Single Interface™, which brings all study data into one unified view: improving visibility, data quality, and decision-making. Let’s talk about how smarter design, technology, and execution can elevate your oncology development programs. Precision Evolution Global #Oncology #ClinicalTrials #PrecisionInClinicalTrials #PrevailInfoWorks #Boston #LifeSciences #Biotech #DataIntegration #ClinicalOperations #RiseAbove #PCTOSummit

Advancing Oncology Trials with Precision. See You in Boston! Prevail InfoWorks will be at the Precision in Clinical Trials Oncology Summit in Boston, November 17–18. This oncology-focused event brings together leaders who are driving innovation in clinical trials. Visit Table 4 to explore real-world oncology case studies, experience a live study exploration, and see how Prevail supports oncology programs from early phase through pivotal trials. Clinical trial failures often stem from challenges in information flow and process management. With a proven track record across some of the industry’s most complex oncology studies, Prevail helps life sciences companies overcome these barriers: improving visibility, data quality, and decision-making. The Single Interface™ from Prevail InfoWorks integrates all your study data into one view: enhancing oversight, uncovering early insights, and enabling faster, smarter execution across oncology development programs. If you are attending, stop by Table 4 and let’s discuss how smarter design, technology, and execution can reshape oncology clinical trials. Precision Evolution Global #Oncology #ClinicalTrials #PrecisionInClinicalTrials #PrevailInfoWorks #Boston #LifeSciences #Biotech #DataIntegration #ClinicalOperations #RiseAbove #PCTOSummit #Conference

Transformative Science: Bringing Vision Back to Those Born Without It Eli Lilly and Company has expanded its gene therapy portfolio with a $475 million deal to acquire global rights to MeiraGTx’s AAV-AIPL1 program, a transformative therapy that restored vision to 11 children born legally blind. The therapy targets Leber congenital amaurosis type 4 (LCA4), a rare inherited retinal disease caused by AIPL1 mutations. Beyond this program, the collaboration gives Lilly access to MeiraGTx’s ophthalmology gene therapy technologies, including novel capsids, AI-designed promoters, and its riboswitch platform for in vivo protein generation. Key Highlights  -Marks a major step in gene therapy’s reach beyond systemic diseases to restore sensory function.  -Highlights Lilly’s growing presence in ophthalmology, complementing its recent eye disease gene therapy acquisitions.  -Demonstrates the power of partnerships between biotech innovation and pharma scale to bring transformative therapies closer to patients. MeiraGTx plans to seek regulatory approval in the U.K. and U.S. by late 2025, moving one step closer to delivering a one-time treatment that could change lives permanently.  How might this redefine what’s possible for patients born with rare genetic conditions? “We are excited to partner with MeiraGTx to bring transformative treatments to patients around the world suffering from eye diseases, starting with AAV-AIPL1, which has shown the unprecedented ability to restore vision in children who were born legally blind.” Andrew Adams, Ph.D., Lilly’s group vice president of molecule discovery, said in the release. Read more in the comment section #GeneTherapy #Ophthalmology #RareDiseases #Biotech #ClinicalResearch #DrugDevelopment #Innovation #EliLilly #MeiraGTx #RiseAbove #Prevail #PrevailInfoWorks

Honoring Those Who Served Today, we stand in gratitude for the men and women who have served our country. Their courage, resilience, and unwavering sense of duty remind us of the strength found in commitment and selflessness. Veterans Day is more than a date on the calendar. It is a moment to pause, reflect, and thank those who put service before self. Their sacrifices protect freedom and opportunities that shape our way of life. To every veteran and their family, we honor you today and every day. #VeteransDay #ThankYouVeterans #Gratitude #Service #Honor #Respect #RiseAbove #Prevail #PrevailInfoWorks

Langer Duo Launches T.Rx Capital with $77.5M Debut Fund Robert Langer, biotech pioneer and co-founder of Moderna, has joined forces with his son Michael Langer to launch T.Rx Capital, a new venture firm focused on biotech, techbio, and tech-enabled services. The firm closed its inaugural fund at $77.5 million, anchored by Langer and backed by high-net-worth individuals and family offices from around the globe. Key Points -T.Rx Capital targets companies at the intersection of biology and technology, including biotech and techbio.  -The fund plans to build a concentrated portfolio of 10–15 companies, writing $5–10 million checks and taking active governance roles.  -Robert Langer serves as Executive Chairman of the firm, leveraging decades of biotech startup and research experience. How will firms like T.Rx Capital shape the next wave of biotech innovation?  What advantages come from combining biotechnologist, businessman, chemical engineer, chemist, and inventor experience with venture capital strategy? “As biology and technology converge, we see a historic opportunity to build scalable platforms that can fundamentally reshape disease treatment.” -Michael Langer Read full article in the comment section #Biotech #VentureCapital #LifeSciences #Innovation #HealthcareInvesting #DrugDevelopment #TechBio #StartupFunding #Research #PrevailInfoWorks #PrevailPartners

Nanobiotix turns to royalty-backed funding to keep its phase 3 cancer drug on track For cash-strapped biotechs, creativity can be as critical as science. Nanobiotix has found a new way to extend its runway leveraging its phase 3-stage, Johnson & Johnson-partnered cancer drug (JNJ-1900 / NBTXR3) to secure $71 million in non-dilutive capital from HealthCare Royalty (HCRx). Deal snapshot:  -$50M upfront, with $21M contingent on future conditions  -Repayment tied to a defined portion of royalties and milestone payments  -Funding expected to sustain operations into early 2028  -NBTXR3 continues in phase 3 trials for locally advanced head and neck cancer This latest royalty-backed loan offers much-needed stability and, importantly, keeps development moving forward. The deal reflects a growing trend among emerging biotechs: leveraging creative, non-dilutive financing and asset-backed partnerships to bridge the gap between late-stage trials and commercialization. Do you see royalty-backed or milestone-based funding as a sustainable solution for advancing late-stage programs? What lessons can other clinical-stage companies take from Nanobiotix’s approach to funding? Is strategic financing now as important as clinical data when it comes to biotech success? “We are excited to partner with Nanobiotix at this pivotal stage of its growth,” HCRx CEO Clarke Futch said in the release. Read the full article in the comment section below #Biotech #Oncology #Nanobiotix #JNJ1900 #NBTXR3 #JohnsonAndJohnson #ClinicalTrials #DrugDevelopment #LifeSciences #FinancingStrategy #RiseAbove #PrevailInfoWorks #Prevail 

Clinical Trials Can Get Spooky.  Deadlines creep closer.  Data hides in the shadows.  Unexpected issues jump out when you least expect them. But you handle it with precision, teamwork, and a clear focus on getting therapies to patients faster.    This Halloween, here’s to every clinical operations professional who keeps trials running smoothly even when things get a little scary. Keep turning the chaos into clarity. Keep Rising Above. #PrevailInfoWorks #ClinicalTrials #ClinicalOperations #Biotech #LifeSciences #ClinicalResearch #DataIntegrity #Teamwork #Halloween #RiseAbove

Missing documents. Missed deadlines. Not anymore. Spreadsheets slow you down. AI-enabled TMF moves you forward Managing essential documents with trackers and email threads slows everything down, especially when every day counts. The Prevail InfoWorks eTMF brings automation and visibility together, giving sponsors and CROs the latest advancement in paperless, real-time collection, filing, tracking of documents, seamlessly. With cloud-based dashboards, teams can spot gaps, monitor site startup, and stay audit-ready without the last-minute scramble. The result? Smoother launches, faster activations, and better compliance with less manual effort. What would your team gain if your TMF was truly automated with AI? How close is your TMF process to being improved with only AI-enabled TMF? #ClinicalTrials #eTMF #ClinicalResearch #ClinicalOperations #PharmaInnovation #Biotechnology #DigitalHealth #HealthcareTechnology #LifeSciences #DataDrivenResearch #PrevailInfoWorks #Prevail #RiseAbove